Alcaftadine 0.25% Versus Olopatadine 0.2% In Prevention Of Ocular Itching In Allergic Conjunctivitis

被引：2
|
作者：
McLaurin, Eugene B. [1 ]
Marsico, Nicholas P. [2 ]
Ciolino, Joseph B. [3 ]
Villanueva, Linda [4 ]
Williams, Julia M. [4 ]
Hollander, David A. [4 ]
机构：
[1] Total Eye Care PA, Memphis, TN USA
[2] East West Eye Inst, Los Angeles, CA USA
[3] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA
[4] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2014年 / 133卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2013.12.986
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
961
引用
收藏
页码：AB278 / AB278
页数：1
相关论文
共 50 条
  • [31] Perception and quality of life associated with the use of olopatadine 0.2% (Pataday™) in patients with active allergic conjunctivitis
    Scoper, Stephen V.
    Berdy, Gregg J.
    Lichtenstein, Steven J.
    Rubin, Jay M.
    Bloomenstein, Marc
    Prouty, Robert E.
    Vogelson, Cullen T.
    Edwards, Michael R.
    Waycaster, Curtis
    Pasquine, Terri
    Gross, Robert D.
    Robertson, Stella M.
    ADVANCES IN THERAPY, 2007, 24 (06) : 1221 - 1232
  • [32] Patient evaluation of azelastine HCl versus olopatadine HCl in the treatment of allergic conjunctivitis
    Oliva, AM
    Slonim, CB
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [33] Perception and quality of life associated with the use of olopatadine 0.2% (Pataday™) in patients with active allergic conjunctivitis
    Stephen V. Scoper
    Gregg J. Berdy
    Steven J. Lichtenstein
    Jay M. Rubin
    Marc Bloomenstein
    Robert E. Prouty
    Cullen T. Vogelson
    Michael R. Edwards
    Curtis Waycaster
    Terri Pasquine
    Robert D. Gross
    Stella M. Robertson
    Advances in Therapy, 2007, 24 : 1221 - 1232
  • [34] Emedastine ophthalmic solution alleviates ocular itching and redness associated with allergic conjunctivitis.
    Lowry, GM
    Abelson, M
    Rubin, JM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1996, 37 (03) : 2731 - 2731
  • [35] Olopatadine 0.2% reduces the primary sign and symptom of allergic conjunctivitis during peak pollen periods
    Greiner, JV
    Abelson, MB
    Gomes, PJ
    Vogelson, CT
    Pasquine, TA
    Gross, RD
    Turner, FD
    Bergamini, MVW
    Robertson, SM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U532 - U532
  • [36] Olopatadine reduces ocular signs and symptoms associated with allergic conjunctivitis 16 hours after instillation
    Abelson, MB
    Gomes, PJ
    Welch, DL
    Pasquine, TA
    Turner, FD
    Bergamini, MVW
    Robertson, SM
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U311 - U311
  • [37] Pharmacodynamic Model to Predict Ocular Itching Outcomes at 24 Hours Post-Treatment with Olopatadine (0.77% or 0.2%)
    Fidler, Matthew L.
    Narvekar, Abhijit
    Covert, David
    Sarangapani, Ramesh
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (02) : AB257 - AB257
  • [38] Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis
    Torkildsen, G. L.
    Gomes, P. J.
    Williams, J. I.
    Gow, J. A.
    McNamara, T. R.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S57 - S57
  • [39] Defining clinically meaningful improvement in ocular itching following treatment with reproxalap in an allergic conjunctivitis field trial
    Raval, Yesha
    Gomes, Paul
    Cavanagh, Bill
    Brady, Todd
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [40] Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: A real-world comparison of efficacy and ocular comfort
    Michael Ganz
    Elizabeth Koll
    Jean Gausche
    Paul Detjen
    Nicholas Orfan
    Advances in Therapy, 2003, 20 : 79 - 91
12345